Prolonged remission of a demyelinating neuropathy in a patient with lymphoma and Sjögren's syndrome after Rituximab therapy

Chronic acquired demyelinating polyneuropathies may be refractory to conventional therapy including corticosteroids, plasma exchange, and intravenous immunoglobulin (Ig) or require long-term immunotherapy to maintain remission. Use of alternative approaches such as Rituximab, an anti-CD20 antibody,...

Full description

Saved in:
Bibliographic Details
Published inJournal of clinical neuromuscular disease Vol. 11; no. 3; p. 127
Main Authors Botez, Stephan A, Herrmann, David N
Format Journal Article
LanguageEnglish
Published United States 01.03.2010
Subjects
Aged
Antibodies, Monoclonal - therapeutic use
Antibodies, Monoclonal, Murine-Derived
Electromyography - methods
Female
Humans
Immunologic Factors - therapeutic use
Lymphoma - complications
Lymphoma - therapy
Neural Conduction - drug effects
Rituximab
Sjogren's Syndrome - complications
Sjogren's Syndrome - therapy
Online AccessGet more information

Cover

More Information
Summary:Chronic acquired demyelinating polyneuropathies may be refractory to conventional therapy including corticosteroids, plasma exchange, and intravenous immunoglobulin (Ig) or require long-term immunotherapy to maintain remission. Use of alternative approaches such as Rituximab, an anti-CD20 antibody, in the treatment of demyelinating polyneuropathy, unrelated to IgM gammopathy and myelin-associated glycoprotein antibodies, has been the subject of only a few case reports. We report the case of a 79-year-old woman with a distal acquired demyelinating polyneuropathy in the context of Sjögren's syndrome, IgG paraproteinemia, and occult lymphoma who has had an excellent and durable response to Rituximab therapy.
ISSN:1537-1611
DOI:10.1097/CND.0b013e3181c50513